Rheumatology Advance Access published online on October 16, 2008
Rheumatology, doi:10.1093/rheumatology/ken395
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Review |
Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis
1Division of Cardiology, Department of Medicine, Geneva University Hospital, Foundation for Medical Researches, Geneva, Switzerland.
Correspondence to:
F. Mach, Division of Cardiology, Department of Medicine, Geneva University Hospital, Foundation for Medical Researches, 64 Avenue Roseraie, 1211 Geneva, Switzerland. E-mail: Francois.Mach{at}medecine.unige.ch
| Abstract |
|---|
RA is characterized by a systemic inflammatory state, in which immune cells and soluble mediators play a crucial role. These inflammatory processes resemble those in other chronic inflammatory diseases, such as atherosclerosis. The chronic systemic inflammation in RA can be considered as an independent risk factor for the development of atherosclerosis, and represents an important field to investigate the reasons of the increase of acute cardiovascular events in RA. In the present review, we focused on several mediators of autoimmunity, inflammation and endothelial dysfunction, which can be considered the most promising targets to prevent atherogenesis in RA. Among several mediators, the pro-inflammatory cytokine TNF-
has been shown as a crucial factor to induce atherosclerosis in RA patients.
KEY WORDS: Rheumatoid arthritis, Cardiovascular, Cytokine and inflammatory mediators, Inflammation, Chemotactic factors
Submitted 20 May 2008;
revised version accepted 10 September 2008.
![]()
CiteULike
Connotea
Del.icio.us What's this?